A new survey from Mashable finds nearly 10 percent of Americans admit to smoking pot before heading into the office. CNBC's Kate Rogers shares the difficulties in testing employees.» Read More
Starbuds of Denver owner Brian Ruden says the next step in his business is to get more "growth capacity" to handle the demand.
InterMune president & CEO Dan Welch says positive drug trial results bring hope to patients with idiopathic pulmonary fibrosis, and discusses the volatility in its stock.
CNBC's Morgan Brennan reports the pharmaceutical companies are developing oral therapies for the condition that could replace current treatments.
At least one analyst at Target pushed for an investigation into payment systems after government and industry reports.
NBC's Pete Williams reports the government has issued guidance for banks servicing legal marijuana businesses. CNBC's Jane Wells provides insight.
Global healthcare company Roche is confident of growth in emerging markets despite the economic slowdown.
Companies and industries that rely on low-income spenders could see a boost to the bottom line thanks to rising wages in many American states.
Michael Morrissey, Exelixis president & CEO, provides insight on clinical research of prostate cancer and its cancer drug Cometriq.
Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.
Eli Lilly Chairman & CEO John Lechleiter provides insight on its rights to an experimental migraine drug.
Eli Lilly Chairman & CEO John Lechleiter discusses its loss of major patents, its current pipeline and when its total costs will normalize.
CNBC's Morgan Brennan reports on the FDA's four expediting pipelines. The approval rates for the drugs in these pipelines tend to be higher than those plodding the more traditional course.
But the delay in packaging the liquid version has not affected supplies of regular Tamiflu, said the Roche unit that makes the medication.
Neurocrine Biosciences' president and CEO Kevin Gorman, Ph. D., provides insight on clinical trials for its tardive dyskinesia treatment.
CNBC's Josh Lipton reports on the HT Growth Fund, which plans to raise $100 million over the next two years for the legal marijuana market.
CNBC's Josh Lipton reports that legal recreational pot businesses could get investment from a fund.
Colorado has issued more than 300 licenses to marijuana dispensaries. Dan Danko, High Times Magazine senior editor, discusses how Colorado is properly regulating pot distribution and explains the rigorous application process to obtain a license.
CNBC's Sara Eisen reports GlaxoSmithKline is becoming the first to stop paying doctors to promote drugs.
Muddled by inconsistent earnings and stock performances, one sector appears tougher and tougher to predict, CNBC's Jim Cramer says.
A medical marijuana dispensary in Central City, Colo.—a small gambling town nestled in the mountains near Denver—just became the first business in the United States licensed to sell marijuana to patrons without a note from their doctors.